Pailin Bio: Subsidiary Hemozyme's Clinical Trial Approved

PaLin Biology announced on April 12th that its wholly-owned subsidiary, Guangdong ShuangLin Biological Pharmaceuticals Co., Ltd., has received the drug clinical trial approval notice for human thrombin issued by the National Medical Products Administration. The approval allows the product to conduct clinical trials for "assisted hemostasis in cases where capillaries and small veins have oozing and slight bleeding, and bleeding control is ineffective or impractical through standard surgical techniques."